All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering Committee About Us Newsletter Contact

Visit:

You're logged in! Click here any time to manage your account or log out.

Steering Committee About Us Newsletter Contact

Brought to you by

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.

Types Therapeutics Congresses Trials Expert Opinions Educational Resources DRUG UPDATES

Multiple Myeloma Types

2021-02-18T12:21:02.000Z

How do I manage the risk of infection in patients treated with immunotherapies?

By Marcia Rato, Alice Hyde

Featured

Joshua Hill

Feb 18, 2021

Bookmark this article

Video series

How I treat

1

23:22

Identifying and treating high-risk patients in 2023

Mohamad Mohty

2

3:05

How to manage bridging therapies prior to CAR T cells in multiple myeloma?

Hermann Einsele

3

3:14

How to identify and mitigate neurologic AEs when treating with CAR-T and...

Hermann Einsele

4

4:08

How I treat patients with MRD after transplantation

4:04

How do I manage the risk of infection in patients treated with...

Joshua Hill

6

8:30

How to treat patients with high-risk multiple myeloma

Jesús San Miguel

During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Joshua Hill, Fred Hutchinson Cancer Research Center, Seattle, US. We asked, How do I manage the risk of infection in patients treated with immunotherapies?

As Joshua Hill discusses this subject, he touches on a number of topics including the use of intravenous or subcutaneous immunoglobulins, and when to vaccinate these patients against COVID-19.